Ascendis Pharma A/S ASND

What this company does

Ascendis Pharma A/S has two marketed products and four product candidates in clinical development in the Endocrinology Rare Disease and Oncology areas. It does not maintain the capability to manufacture finished drug products and instead uses contract manufacturers to manufacture finished drug product of its TransCon products and product candidates intended for commercial or clinical use. YORVIPATH (palopegteriparatide) has been approved by the U.S. Food and Drug Administration and authorized by the European Commission and other regulatory agencies for the treatment of adults with hypoparathyroidism. Through December 31, 2025, more than 5,300 unique patients had been prescribed YORVIPATH by nearly 2,400 prescribing healthcare providers in the U.S. SKYTROFA (lonapegsomatropin-tcgd) has been approved by the FDA for the treatment of pediatric patients at least one year old who weigh at least 11.5 kg and have growth hormone deficiency, and for growth hormone replacement in adults with the condition. In the United States, SKYTROFA has been commercially available for prescription since October 2021.

Written from the business description in Ascendis Pharma A/S's annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.